Foresee Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	870.02	479.52	1,367	1,010	689.51	871.44
Short-Term Investments	21.96	-	-	150	-	100
Trading Asset Securities	-	-	-	-	-	297.47
Cash & Short-Term Investments	891.98	479.52	1,367	1,160	689.51	1,269
Cash Growth	-13.18%	-64.93%	17.90%	68.19%	-45.66%	-21.76%
Accounts Receivable	81.06	43.48	32.33	65.91	16.27	-
Other Receivables	11.4	17.28	26.55	22.18	10.13	5.73
Receivables	92.46	60.76	58.88	88.09	26.4	5.73
Inventory	139.67	144.71	183.87	126.8	176.41	24.88
Prepaid Expenses	90.89	80.02	132.48	23.56	22.75	3.9
Other Current Assets	10.17	220.7	75	192.5	-	-
Total Current Assets	1,225	985.71	1,818	1,591	915.06	1,303
Property, Plant & Equipment	198.55	207.16	217.62	135.01	142.39	91.19
Other Intangible Assets	106.36	111.14	117.79	126.81	140.96	155.14
Long-Term Deferred Tax Assets	-	1.25	1.31	1.23	1.22	1.1
Other Long-Term Assets	49.9	5.13	4.9	7.76	104.39	90.58
Total Assets	1,943	1,310	2,159	1,861	1,304	1,641
Accounts Payable	21.1	16.57	64.42	12.13	22.85	-
Accrued Expenses	-	7.31	5.37	120.71	78.47	61.68
Short-Term Debt	-	197	150	200	-	-
Current Portion of Long-Term Debt	-	-	5	-	-	-
Current Portion of Leases	14.02	14.23	12.41	15.14	15.52	10.2
Current Income Taxes Payable	20.57	11.47	8.82	10.42	4.95	-
Current Unearned Revenue	-	-	50.03	105.48	1.01	0.78
Other Current Liabilities	34.31	39.71	97.16	6.96	6.38	1.79
Total Current Liabilities	90.01	286.3	393.21	470.83	129.17	74.45
Long-Term Debt	368.36	-	92.92	-	-	-
Long-Term Leases	16.89	20.51	-	13.12	25.8	6.45
Long-Term Unearned Revenue	72.62	72.62	72.62	131.67	237.15	239.17
Long-Term Deferred Tax Liabilities	-	1.35	1.41	1.32	1.32	1.19
Total Liabilities	547.87	380.78	560.15	616.93	393.43	321.26
Common Stock	1,575	1,575	1,548	1,358	1,182	1,179
Additional Paid-In Capital	6,133	6,087	5,906	4,617	3,424	3,372
Retained Earnings	-6,287	-6,694	-5,811	-4,730	-3,693	-3,221
Comprehensive Income & Other	-27.03	-38.86	-44.56	-1.49	-1.54	-10.21
Shareholders' Equity	1,395	929.61	1,599	1,245	910.58	1,320
Total Liabilities & Equity	1,943	1,310	2,159	1,861	1,304	1,641
Total Debt	399.26	231.74	260.33	228.26	41.32	16.65
Net Cash (Debt)	492.72	247.78	1,107	931.42	648.19	1,252
Net Cash Growth	-43.46%	-77.62%	18.85%	43.70%	-48.24%	-16.05%
Net Cash Per Share	3.72	1.60	8.06	7.32	5.49	10.67
Filing Date Shares Outstanding	203.46	157.54	154.79	135.82	118.17	117.94
Total Common Shares Outstanding	203.46	157.54	154.79	135.82	118.17	117.94
Working Capital	1,135	699.41	1,424	1,120	785.89	1,229
Book Value Per Share	6.86	5.90	10.33	9.16	7.71	11.19
Tangible Book Value	1,288	818.47	1,481	1,118	769.62	1,165
Tangible Book Value Per Share	6.33	5.20	9.57	8.23	6.51	9.88
Land	-	123.07	123.07	-	-	-
Buildings	-	9.96	9.96	-	-	-
Machinery	-	227.88	226.59	209.45	171.58	136.94
Construction In Progress	-	-	-	4.9	20.39	4.4
Leasehold Improvements	-	30.44	30.44	30.44	7.71	7.71